Hyper-inflammatory responses in COVID-19 and anti-inflammatory therapeutic approaches

키워드

참고문헌 (92)

1. Zhu N, "A novel Coronavirus from patients with pneumonia in China, 2019", N Engl J Med, 382, pp.727~733 (2020)
2. Fung TS, "Human Coronavirus : hostpathogen interaction", Annu Rev Microbiol, 73, pp.529~557 (2019)
3. Lu RJ, "Genomic characterisation and epidemiology of 2019 novel coronavirus : implications for virus origins and receptor binding", Lancet, 395, pp.565~574 (2020)
4. Wan YS, "Receptor recognition by the novel Coronavirus from Wuhan : an analysis based on decade-long structural studies of SARS Coronavirus", J Virol, 94, pp.e00127-20~ (2020)
5. Fauci AS, "Covid-19-navigating the uncharted", N Engl J Med, 382, pp.1268~1269 (2020)
6. Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
7. Richardson S, "Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area", JAMA, 323, pp.2052~2059 (2020)
8. Mehta P, "COVID-19 : consider cytokine storm syndromes and immunosuppression", Lancet, 395, pp.1033~1034 (2020)
9. Gustine JN, "Immunopathology of Hyperinflammation in COVID-19", Am J Pathol, 191, pp.4~17 (2021)
10. Zhou F, "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study", Lancet, 395, pp.1054~1062 (2020)
11. Del Valle DM, "An inflammatory cytokine signature predicts COVID-19 severity and survival", Nat Med, 26, pp.1636~1643 (2020)
12. Group RC, "Dexamethasone in hospitalized patients with Covid-19", N Engl J Med, 384, pp.693~704 (2021)
13. Kim You-Me, "Type I and III interferon responses in SARS-CoV-2 infection", Experimental and Molecular Medicine, 53, pp.1~11 (2021), 생화학분자생물학회[DOI]
14. Mesev EV, "Decoding type I and III interferon signalling during viral infection", Nat Microbiol, 4, pp.914~924 (2019)
15. Park A, "Type I and type III interferons-induction, signaling, evasion, and application to combat COVID-19", Cell Host Microbe, 27, pp.870~878 (2020)
16. Ribero MS, "Interplay between SARS-CoV-2 and the type I interferon response", PLoS Pathog, 16, pp.e1008737~ (2020)
17. 최호준, "Roles of Type I and III Interferons in COVID-19", Yonsei Medical Journal, 62(5), pp.381~390 (2021), 연세대학교의과대학[DOI]
18. Perico L, "Immunity, endothelial injury and complement-induced coagulopathy in COVID-19", Nat Rev Nephrol, 17, pp.46~64 (2021)
19. Lee JS, "Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19", Sci Immunol, 5, pp.eabd1554~ (2020)
20. Galani IE, "Untuned antiviral immunity in COVID-19 revealed by temporal type I", III interferon patterns and flu comparison, 2021, pp.22, 32~40
21. Wang D, "Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirusinfected pneumonia in Wuhan, China", JAMA, 323, pp.1061~1069 (2020)
22. Liu J, "Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage", J Transl Med, 18, pp.206~ (2020)
23. Carissimo G, "Whole blood immunophenotyping uncovers immature neutrophil-to-VD2T-cell ratio as an early marker for severe COVID-19", Nat Commun, 11, pp.5243~ (2020)
24. Zhou Z, "Heightened innate immune responses in the respiratory tract of COVID-19patients", Cell Host Microbe, 27, pp.883~890 (2020)
25. Chua RL, "COVID-19severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis", Nat Biotechnol, 38, pp.970~979 (2020)
26. Liao M, "Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19", Nat Med, 26, pp.842~844 (2020)
27. Wauters E, "Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages", Cell Res, 31, pp.272~290 (2021)
28. Li J, "Virus-host interactome and proteomic survey reveal potential virulence factors influencing SARS-CoV-2 pathogenesis", Med(N Y), 2, pp.99~112 (2021)
29. Middleton EA, "Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome", Blood, 136, pp.1169~1179 (2020)
30. Zuo Y, "Neutrophil extracellular traps in COVID-19", JCI Insight, 5, pp.e138999~ (2020)
31. Bost P, "Host-viral infection maps reveal signatures of severe COVID-19 patients", Cell, 181, pp.1475~1488 (2020)
32. Ren X, "COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas", Cell, 184, pp.1895~1913 (2021)
33. Wen W, "Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing", Cell Discov, 6, pp.31~ (2020)
34. Guo C, "Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm", Nat Commun, 11, pp.3924~ (2020)
35. Williams DM, "Clinical pharmacology of corticosteroids", Respir Care, 63, pp.655~670 (2018)
36. Brattsand R, "Cytokine modulation by glucocorticoids : mechanisms and actions in cellular studies", Aliment Pharmacol Ther 10 Suppl, 2, pp.81~90 (1996)
37. Pulakurthi YS, "Corticosteroid therapy for COVID-19 : A systematic review and meta-analysis of randomized controlled trials", Medicine(Baltimore), 100, pp.e25719~ (2021)
38. Johns M, "A review of the evidence for corticosteroids in COVID-19", J Pharm Pract (2021)
39. Sebba A, "Tocilizumab : the first interleukin-6-receptor inhibitor", Am J Health Syst Pharm, 65, pp.1413~1418 (2008)
40. Le RQ, "FDA approval summary : Tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome", Oncologist, 23, pp.943~947 (2018)
41. Xu X, "Effective treatment of severe COVID-19 patients with tocilizumab", Proc Natl Acad Sci U S A, 117, pp.10970~10975 (2020)
42. Sciascia S, "Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19", Clin Exp Rheumatol, 38, pp.529~532 (2020)
43. Guaraldi G, "Tocilizumab in patients with severe COVID-19 : a retrospective cohort study", Lancet Rheumatol, 2, pp.e474~ (2020)
44. Gupta S, "Association between early treatment with Tocilizumab and mortality among critically ill patients with COVID-19", JAMA Intern Med, 181, pp.41~51 (2021)
45. Stone JH, "Efficacy of Tocilizumab in patients hospitalized with Covid-19", N Engl J Med, 383, pp.2333~2344 (2020)
46. Leaf DE, "Tocilizumab in Covid-19", N Engl J Med, 384, pp.86~87 (2021)
47. Salama C, "Tocilizumab in patients hospitalized with Covid-19 pneumonia", N Engl J Med, 384, pp.20~30 (2021)
48. Rosas IO, "Tocilizumab in hospitalized patients with severe Covid-19 pneumonia", N Engl J Med, 384, pp.1503~1516 (2021)
49. Della-Torre E, "Interleukin-6 blockade with sarilumab in severe COVID-19pneumonia with systemic hyperinflammation : an openlabel cohort study", Ann Rheum Dis, 79, pp.1277~1285 (2020)
50. Lescure FX, "Sarilumab in patients admitted to hospital with severe or critical COVID-19 : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet Respir Med, 9, pp.522~532 (2021)
51. Morinobu A, "JAK inhibitors for the treatment of rheumatoid arthritis", Immunol Med, 43, pp.148~155 (2020)
52. Hoang TN, "Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques", Cell, 184, pp.460~475 (2021)
53. Kalil AC, "Baricitinib plus Remdesivir for hospitalized adults with Covid-19", N Engl J Med, 384, pp.795~807 (2021)
54. Titanji BK, "Use of Baricitinib in patients with moderate to severe Coronavirus disease 2019", Clin Infect Dis, 72, pp.1247~1250 (2021)
55. Capochiani E, "Ruxolitinib rapidly reduces acute respiratory distress syndrome in COVID-19 disease", Analysis of data collection From RESPIRE protocol. Front Med(Lausanne), 7, pp.466~ (2020)
56. Cao Y, "Ruxolitinib in treatment of severe coronavirus disease 2019(COVID-19) : a multicenter, single-blind, randomized controlled trial", J Allergy Clin Immunol, 146, pp.137~146 (2020)
57. Raposo G, "Extracellular vesicles : exosomes, microvesicles, and friends", J Cell Biol, 200, pp.373~383 (2013)
58. Thery C, "Exosomes : composition, biogenesis and function", Nat Rev Immunol, 2, pp.569~579 (2002)
59. Pegtel DM, "Exosomes", Annu Rev Biochem, 88, pp.487~514 (2019)
60. Peng H, "Exosome : a significant nano-scale drug delivery carrier", J Mater Chem B, 8, pp.7591~7608 (2020)
61. Caby MP, "Exosomal-like vesicles are present in human blood plasma", Int Immunol, 17, pp.879~887 (2005)
62. Pisitkun T, "Identification and proteomic profiling of exosomes in human urine", Proc Natl Acad Sci U S A, 101, pp.13368~13373 (2004)
63. Michael A, "Exosomes from human saliva as a source of microRNA biomarkers", Oral Dis, 16, pp.34~38 (2010)
64. Admyre C, "Exosomes with immune modulatory features are present in human breast milk", J Immunol, 179, pp.1969~1978 (2007)
65. Vojtech L, "Exosomes in human semen carry a distinctive repertoire of small noncoding RNAs with potential regulatory functions", Nucleic Acids Res, 42, pp.7290~7304 (2014)
66. Jafari D, "Designer exosomes : a new platform for biotechnology therapeutics", BioDrugs, 34, pp.567~586 (2020)
67. Zipkin M, "Exosome redux", Nat Biotechnol, 37, pp.1395~1400 (2019)
68. Kim J, "Platform technologies and human cell lines for the production of therapeutic exosomes", Extracell Vesicles Circ Nucl Acids, 2, pp.3~17 (2021)
69. Caplan AI, "Mesenchymal stem cells as trophic mediators", J Cell Biochem, 98, pp.1076~1084 (2006)
70. Baek G, "Mesenchymal stem cell-derived extracellular vesicles as therapeutics and as a drug delivery platform", Stem Cells Transl Med, 8, pp.880~886 (2019)
71. Suh JH, "Therapeutic application of exosomes in inflammatory dis-eases", Int J Mol Sci, 22, pp.1144~ (2021)
72. Sengupta V, "Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19", Stem Cells Dev, 29, pp.747~754 (2020)
73. Lim SK, "Re : "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19"by Sengupta et al", Stem Cells Dev, 29, pp.877~878 (2020)
74. Sun D, "A novel nanoparticle drug delivery system : the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes", Mol Ther, 18, pp.1606~1614 (2010)
75. Kim MS, "Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells", Nanomedicine, 12, pp.655~664 (2016)
76. Alvarez-Erviti L, "Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes", Nat Biotechnol, 29, pp.341~345 (2011)
77. Lamichhane TN, "Oncogene knockdown via active loading of small rnas into extracellular vesicles by sonication", Cell Mol Bioeng, 9, pp.315~324 (2016)
78. Hood JL, "Post isolation modification of exosomes for nanomedicine applications", Nanomedicine(Lond), 11, pp.1745~1756 (2016)
79. Kamerkar S, "Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer", Nature, 546, pp.498~503 (2017)
80. Hood JL, "Maximizing exosome colloidal stability following electroporation", Anal Biochem, 448, pp.41~49 (2014)
81. Tang TT, "Extracellular vesicle-encapsulated IL-10 as novel nanotherapeutics against ischemic AKI", Sci Adv, 6, pp.eaaz0748~ (2020)
82. Dooley K, "A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties", Mol Ther, 29, pp.1729~1743 (2021)
83. Yim N, "Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein-protein interaction module", Nat Commun, 7, pp.12277~ (2016)
84. Shalitin D, "Regulation of Arabidopsis cryptochrome 2 by blue-light-dependent phosphorylation", Nature, 417, pp.763~767 (2002)
85. Kennedy MJ, "Rapid blue-light-mediated induction of protein interactions in living cells", Nat Methods, 7, pp.973~975 (2010)
86. Choi H, "Exosome-based delivery of super-repressor IkappaBalpha relieves sepsisassociated organ damage and mortality", Sci Adv, 6, pp.eaaz6980~ (2020)
87. Sheller-Miller S, "Exosomal delivery of NF-kappaB inhibitor delays LPS-induced preterm birth and modulates fetal immune cell profile in mouse models", Sci Adv, 7, pp.eabd3865~ (2021)
88. Kim S, "Exosome-based delivery of super-repressor IkappaBalpha ameliorates kidney ischemia-reperfusion injury", Kidney Int, 100, pp.570~584 (2021)
89. Choi Hojun, "Biodistribution of Exosomes and Engineering Strategies for Targeted Delivery of Therapeutic Exosomes", 조직공학과 재생의학, 18(4), pp.499~511 (2021), 한국조직공학과 재생의학회[DOI]
90. Imai T, "Macrophage-dependent clearance of systemically administered B16BL6-derived exosomes from the blood circulation in mice", J Extracell Vesicles, 4, pp.26238~ (2015)
91. Kircheis R, "NF-kappaB pathway as a potential target for treatment of critical stage COVID-19patients", Front Immunol, 11, pp.598444~ (2020)
92. Hariharan A, "The role and therapeutic potential of nf-kappa-b Pathway in Severe COVID-19 patients", Inflammopharmacology, 29, pp.91~100 (2021)

관련 논문AI추천